{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T12:40:03Z","timestamp":1776602403584,"version":"3.51.2"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014103","name":"Key Technology Research and Development Program of Shandong","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.ejmech.2020.112241","type":"journal-article","created":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T12:58:19Z","timestamp":1584363499000},"page":"112241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions"],"prefix":"10.1016","volume":"193","author":[{"given":"Xiang","family":"Nan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sen-Biao","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin-Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Chao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2020.112241_bib1","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1126\/science.1846706","article-title":"Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product","volume":"251","author":"Bottaro","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2020.112241_bib2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/318385a0","article-title":"The human met oncogene is related to the tyrosine kinase oncogenes","volume":"318","author":"Dean","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2020.112241_bib3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrc779","article-title":"Scatter-factor and semaphorin receptors: cell signaling for invasive growth","volume":"2","author":"Trusolino","year":"2002","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.ejmech.2020.112241_bib4","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nrm1261","article-title":"Met, metastasis, motility and more","volume":"4","author":"Birchmeier","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2020.112241_bib5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.biopha.2017.12.045","article-title":"Overexpression of ING5 inhibits HGF-induced proliferation, invasion and EMT in thyroid cancer cells via regulation of the c-Met\/PI3K\/Akt signaling pathway","volume":"98","author":"Gao","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2020.112241_bib6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1432-1327.1999.00507.x","article-title":"Deregulation of the signaling pathways controlling urokinase production","volume":"263","author":"Aguirre Ghiso","year":"1999","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ejmech.2020.112241_bib7","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1073\/pnas.91.11.4731","article-title":"Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor\/scatter factor autocrine stimulation","volume":"91","author":"Rong","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2020.112241_bib8","first-page":"853","article-title":"Autocrine hepatocyte growth factor\/scatter factor-Met signaling induces transformation and the invasive\/metastastic phenotype in C127 cells","volume":"13","author":"Jeffers","year":"1996","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2020.112241_bib9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1073\/pnas.94.2.701","article-title":"Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor\/scatter\u2009factor","volume":"94","author":"Takayama","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2020.112241_bib10","first-page":"5157","article-title":"c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype","volume":"58","author":"Otsuka","year":"1998","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2020.112241_bib11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.lungcan.2018.09.008","article-title":"MET amplification increases the metastatic spread of EGFR-mutated NSCLC","volume":"125","author":"Baldaccia","year":"2018","journal-title":"Lung Canc."},{"key":"10.1016\/j.ejmech.2020.112241_bib12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.lungcan.2019.04.028","article-title":"c-MET as a biomarker in patients with surgically resected non-small cell lung cancer","volume":"133","author":"Tsakonas","year":"2019","journal-title":"Lung Canc."},{"key":"10.1016\/j.ejmech.2020.112241_bib13","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1002\/ijc.24554","article-title":"Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients","volume":"125","author":"Toiyama","year":"2009","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.ejmech.2020.112241_bib14","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/ijc.11471","article-title":"Increase of AKT\/PKB expression correlates with gleason pattern in human prostate cancer","volume":"107","author":"Liao","year":"2003","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.ejmech.2020.112241_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2004.09.044","article-title":"c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention","volume":"225","author":"Christensen","year":"2005","journal-title":"Canc. Lett."},{"key":"10.1016\/j.ejmech.2020.112241_bib16","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1200\/JCO.2008.19.1635","article-title":"Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients","volume":"27","author":"Cappuzzo","year":"2009","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejmech.2020.112241_bib17","doi-asserted-by":"crossref","first-page":"24500","DOI":"10.1074\/jbc.M003145200","article-title":"Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression","volume":"275","author":"Graff","year":"2000","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib18","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1158\/0008-5472.CAN-05-3329","article-title":"Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor\/c-Met\u2013dependent human tumors","volume":"66","author":"Burgess","year":"2006","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2020.112241_bib19","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1158\/0008-5472.CAN-07-5960","article-title":"MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival","volume":"68","author":"Jin","year":"2008","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2020.112241_bib20","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1593\/neo.81536","article-title":"Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in\u00a0vivo","volume":"11","author":"van der Horst","year":"2009","journal-title":"Neoplasia"},{"key":"10.1016\/j.ejmech.2020.112241_bib21","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2174\/187152009787313792","article-title":"From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer","volume":"9","author":"Dussault","year":"2009","journal-title":"Anti Canc. Agents Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib22","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1074\/jbc.M705774200","article-title":"c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations","volume":"283","author":"Bellon","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib23","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.bmc.2016.02.003","article-title":"Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio) semicarbazones as c-Met kinase inhibitors","volume":"24","author":"Zhai","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib24","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.bioorg.2016.12.002","article-title":"Discovery of imidazopyridine derivatives as novel c-Met kinase inhibitors: synthesis, SAR study, and biological activity","volume":"70","author":"Yang","year":"2017","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib25","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bioorg.2017.11.006","article-title":"Design, synthesis and molecular modeling studies of new series of antitumor 1,2,4-triazines with potential c-Met kinase inhibitory activity","volume":"76","author":"El-Wakil","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejmech.2017.03.085","article-title":"Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization","volume":"134","author":"Zhao","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib27","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ejmech.2017.11.073","article-title":"Discovery, optimization and biological evaluation for novel c-Met kinase inhibitors","volume":"143","author":"Yuan","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib28","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ejmech.2019.06.033","article-title":"2,7-naphthyridinone-based MET kinase inhibitors: a promising novel scaffold for antitumor drug development","volume":"178","author":"Zhuo","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib29","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1021\/acs.jmedchem.5b01716","volume":"59","author":"Boezio","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib30","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.4161\/cc.7.9.5827","article-title":"c-Met inhibitors with different binding modes: two is better than one","volume":"7","author":"Dussault","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejmech.2020.112241_bib31","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.1038\/sj.onc.1207691","article-title":"The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants","volume":"23","author":"Berthou","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2020.112241_bib32","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.1016\/j.bmc.2013.10.028","article-title":"Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors","volume":"21","author":"Matsumoto","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib33","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejmech.2018.11.057","article-title":"Discovery of N1-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)-N3-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)urea as a multi-tyrosine kinase inhibitor for drug-sensitive and drug-resistant cancers treatment","volume":"163","author":"Qi","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib34","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1021\/jm2007613","article-title":"Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)","volume":"54","author":"Cui","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib35","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejmech.2016.04.035","article-title":"Discovery of a novel 6,7-disubstituted-4-(2-fluorophenoxy)quinolines bearing 1,2,3-triazole-4-carboxamide moiety as potent c-Met kinase inhibitors","volume":"119","author":"Liu","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2174\/1871520611009010007","article-title":"Discovery of small molecule c-Met inhibitors: evolution and profiles of clinical candidates","volume":"10","author":"Underiner","year":"2010","journal-title":"Anti Canc. Agents Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib37","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ejmech.2016.07.059","article-title":"Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing 1,2,4-triazolone moiety as c-Met kinase inhibitors","volume":"123","author":"Liu","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib38","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1021\/jm800043g","article-title":"Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase","volume":"51","author":"Albrecht","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib39","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.1021\/jm8006189","article-title":"Design, synthesis, and biological evaluation of potent c-Met inhibitors","volume":"51","author":"D\u2019Angelo","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib40","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejmech.2016.04.062","article-title":"Synthesis and biological evaluation of 4-(2-fluorophenoxy)-3,3\u2032-bipyridine derivatives as potential c-met inhibitors","volume":"120","author":"Zhao","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib41","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.bioorg.2018.01.037","article-title":"Discovery of thinopyrimidine-triazole conjugates as c-Met targeting and apoptosis inducing agents","volume":"77","author":"Wang","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib42","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.bmc.2016.12.002","article-title":"Design, synthesis and biological evaluation of novel 4-(2-fluorophenoxy)quinoline derivatives as selective c-Met inhibitors","volume":"25","author":"Wang","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib43","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1016\/j.bmc.2013.04.013","article-title":"Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors","volume":"21","author":"Li","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib44","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ejmech.2018.01.061","article-title":"Identification of novel N1-(2-aryl-1,3-thiazolidin-4-one)-N3-aryl ureas showing potent multi-tyrosine kinase inhibitory activities","volume":"146","author":"Qi","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib45","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ejmech.2018.08.066","article-title":"Synthesis and antiproliferative activity of 6,7-disubstituted-4-phenoxyquinoline derivatives bearing the 1,8-naphthyridin-2-one moiety","volume":"158","author":"Tang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib46","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1016\/j.bmc.2015.06.026","article-title":"Design and biological evaluation of novel 4-(2-fluorophenoxy)quinoline derivatives bearing an imidazolone moiety as c-Met kinase inhibitors","volume":"23","author":"Liao","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib47","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.1016\/j.bmc.2017.06.037","article-title":"Design, synthesis and biological evaluation of novel 4-phenoxyquinoline derivatives containing 3-oxo-3,4-dihydroquinoxaline moiety as c-Met kinase inhibitors","volume":"25","author":"Liu","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib48","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1021\/ar9502083","article-title":"Multiple-component condensation strategies for combinatorial library synthesis","volume":"29","author":"Armstrong","year":"1996","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejmech.2020.112241_bib49","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1021\/cr0505728","article-title":"Recent developments in isocyanide based multicomponent reactions in applied chemistry","volume":"106","author":"D\u00f6mling","year":"2006","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2020.112241_bib50","doi-asserted-by":"crossref","first-page":"7134","DOI":"10.1002\/anie.200601872","article-title":"Cascade reactions in total synthesis","volume":"45","author":"Nicolaou","year":"2006","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2020.112241_bib51","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1002\/anie.200603129","article-title":"Asymmetric organocatalytic domino reactions","volume":"46","author":"Enders","year":"2007","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2020.112241_bib52","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1021\/cr800296p","article-title":"Natural product synthesis using multicomponent reaction strategies","volume":"109","author":"Tour\u00e9","year":"2009","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2020.112241_bib53","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1021\/cr100233r","article-title":"Chemistry and biology of multicomponent reactions","volume":"112","author":"D\u00f6mling","year":"2012","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2020.112241_bib54","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.cbpa.2008.02.004","article-title":"Isocyanide-based multicomponent reactions in drug discovery","volume":"12","author":"Akritopoulou-Zanze","year":"2008","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2020.112241_bib55","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.2174\/0929867023368719","article-title":"The application of multi-component reactions in drug discovery","volume":"9","author":"Weber","year":"2002","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib56","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2174\/0929867033368600","article-title":"Multi-component reactions: emerging chemistry in drug discovery \u2018from xylocain to crixivan\u2019","volume":"10","author":"Hulme","year":"2003","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib57","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1002\/1521-3773(20000915)39:18<3168::AID-ANIE3168>3.0.CO;2-U","article-title":"Multicomponent reactions with isocyanides","volume":"39","author":"D\u00f6mling","year":"2000","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2020.112241_bib58","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S1367-5931(02)00328-9","article-title":"Recent advances in isocyanide-based multicomponent chemistry","volume":"6","author":"D\u00f6mling","year":"2002","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2020.112241_bib59","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1021\/ar020258p","article-title":"Strategies for heterocyclic construction via novel multicomponent reactions based on isocyanides and nucleophilic carbenes","volume":"36","author":"Nair","year":"2003","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejmech.2020.112241_bib60","doi-asserted-by":"crossref","first-page":"14039","DOI":"10.1021\/jacs.5b09117","article-title":"Phosphoric acid-catalyzed asymmetric classic passerini reaction","volume":"137","author":"Zhang","year":"2015","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2020.112241_bib61","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1021\/acs.orglett.5b00849","article-title":"Unexpected synthesis of 5,6-dihydropyridin-2(1H)-ones by a domino Ugi\/Aldol\/Hydrolysis reaction starting from Baylis-Hillman phosphonium salts","volume":"17","author":"Zeng","year":"2015","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2020.112241_bib62","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/80100053","article-title":"The chemistry of isocyanides, their multicomponent reactions and their libraries","volume":"8","author":"Ugi","year":"2003","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2020.112241_bib63","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1039\/b810083g","article-title":"Using the Ugi multicomponent condensation reaction to prepare families of chromophore appended azamacrocycles and their complexes","author":"Main","year":"2008","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2020.112241_bib64","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ejmech.2014.06.068","article-title":"Design, synthesis and structure\u2013activity relationships of novel 4-phenoxyquinoline derivatives containing pyridazinone moiety as potential antitumor agents","volume":"83","author":"Zhou","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib65","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.bmcl.2008.11.037","article-title":"Lead identification to generate 3-cyanoquinoline inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment","volume":"19","author":"Miller","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2020.112241_bib66","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1021\/jm201331s","article-title":"Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series","volume":"55","author":"Liu","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib67","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1039\/C3CS60015G","article-title":"Recent advances in the synthesis of pyrroles by multicomponent reactions","volume":"43","author":"Est\u00e9vez","year":"2014","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2020.112241_bib68","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ejmech.2014.01.038","article-title":"Toward synthesis of third-generation spin-labeled podophyllotoxin derivatives using isocyanide multicomponent reactions","volume":"75","author":"Kou","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib69","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1016\/j.bmc.2019.05.007","article-title":"Design, synthesis and evaluation of sulfonylurea-containing 4-phenoxyquinolines as highly selective c-Met kinase inhibitors","volume":"27","author":"Nan","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib70","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/ng.2330","article-title":"Activation of the AXL kinase causes resistance to EGFR targeted therapy in lung cancer","volume":"44","author":"Zhang","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2020.112241_bib71","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1158\/0008-5472.CAN-10-4433","article-title":"A\u00a0drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients","volume":"71","author":"Tiedt","year":"2011","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2020.112241_bib72","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1349-7006.2009.01343.x","article-title":"E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models","volume":"101","author":"Nakagawa","year":"2010","journal-title":"Canc. Sci."},{"key":"10.1016\/j.ejmech.2020.112241_bib73","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1021\/jm800401t","article-title":"Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-Hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458)","volume":"51","author":"Liu","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib74","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1021\/jm800791f","article-title":"Directed discovery of agents targeting the Met tyrosine kinase domain by virtual screening","volume":"52","author":"Peach","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112241_bib75","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1021\/jm800476q","article-title":"Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activities","volume":"51","author":"Kim","year":"2008","journal-title":"J.\u00a0Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420302087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420302087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:09:05Z","timestamp":1759327745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523420302087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":75,"alternative-id":["S0223523420302087"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112241","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112241","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112241"}}